Imunon, Inc. Long-Term Debt, Maturity, after Year Five
Imunon, Inc. (IMNN) had Long-Term Debt, Maturity, after Year Five of $416.67 thousand as of 2018-12-31, per its 10-K filed 2019-03-29.
Discontinued › Notes › Commitment and Contingencies › Long-Term Debt, Fiscal Year Maturity
us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive · last filed 2019-03-29
- 2018-12-31: Long-Term Debt, Maturity, after Year Five $416.67K.
- 2018-09-30: Long-Term Debt, Maturity, after Year Five $416.67K.
- 2018-06-30: Long-Term Debt, Maturity, after Year Five $416.67K.
| Period end | Long-Term Debt, Maturity, after Year Five |
|---|---|
| 2018-12-31 | $416.67K 10-K · filed 2019-03-29 |
| 2018-09-30 | $416.67K 10-Q · filed 2018-11-14 |
| 2018-06-30 | $416.67K 10-Q · filed 2018-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Traws Pharma, Inc. (TRAW) | United States | $0.009B | -0.58 |
| Alzamend Neuro, Inc. (ALZN) | United States | $0.009B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| FibroBiologics, Inc. (FBLG) | United States | $0.009B | -0.27 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |